Yaqrit appoints new CEO Troels Jordansen to implement late clinical development and commercial strategy

Company Updates - Yaqrit, a late-stage biotech and medtech company, announced the appointment of Troels Jordansen as its new Chief Executive Officer [1] - Troels Jordansen replaces Professor Rajiv Jalan, Yaqrit's Founder and Interim CEO, who will continue to lead the clinical and scientific development [2] - The company is preparing several late-stage trials for its products targeting complications of advanced liver disease and is set to launch a phase 3 study [1] New CEO's Background and Vision - Troels Jordansen brings extensive experience in strategic planning, partnerships, and fundraising, having raised over €200 million and closed deals worth €500 million [3] - His previous roles include CEO of Glycostem Therapeutics, where he oversaw fundraising for NK cell cancer therapies, and leadership positions at Clinical Cell Culture, IsoTis, Genzyme Tissue Repair, and Johnson & Johnson Orthopaedic [3] - Jordansen emphasized his focus on assembling an effective team for clinical and corporate development, leveraging Yaqrit's late-stage pipeline and improving competitive environment [3] Industry Context - Decompensated cirrhosis affects over 10 million patients annually, with median survival dropping from over 12 years in compensated cirrhosis to 2-3 years in decompensated cases and less than 3 months for those with multiorgan failure [7] - Yaqrit's pipeline includes novel therapeutics in phase 2/3 trials and two medical devices entering registrational trials, addressing acute and chronic treatments for advanced cirrhosis and acute-on-chronic liver failure [5] Upcoming Events - Yaqrit's management, including Troels Jordansen, will be available during JPM25 in San Francisco from January 13-16, 2025 [4]